Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma - PubMed
5 hours ago
- #cytokine release syndrome
- #dexamethasone
- #multiple myeloma
- The article discusses the use of dexamethasone in managing cytokine release syndrome (CRS) linked to talquetamab therapy.
- Talquetamab is used for patients with relapsed or refractory multiple myeloma.
- CRS is a known side effect of talquetamab, and dexamethasone is employed to control this adverse reaction.